Galderma (U.K) Ltd

Meridien House, 69-71 Clarendon Road, Watford, Hertfordshire, WD17 1DS, UK
Telephone: +44 (0)1923 208950
Fax: +44 (0)1923 208998
Medical Information e-mail: info.uk@galderma.com


Summary of Product Characteristics last updated on the eMC: 22/06/2010
SPC Calmurid HC Cream


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Calmurid HC 10%/5%/1% Cream


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Urea 10.0% w/w

Lactic Acid 5.0% w/w

Hydrocortisone 1.0% w/w

For a full list of excipients, see section 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM
Cream for topical (cutaneous) use.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

To be used topically for the treatment of atopic eczema, Besniers prurigo, acute and chronic allergic eczema, neurodermatitis and other hyperkeratotic skin conditions with accompanying inflammation.


Go to top of the page
4.2 Posology and method of administration

For external use only.

Adults, elderly and children:

Apply twice daily to the affected area after bathing or washing. Moist lesions should be treated as to dry them before using Calmurid HC.


Go to top of the page
4.3 Contraindications

Skin tuberculosis, viral infections accompanied by dermal manifestations e.g. herpes simplex, vaccinia, chicken pox and measles. Syphilitic skin lesions. In concurrent mycotic infections, the cream should be complemented with antimycotic treatment. Hypersensitivity to any constituent of the product.


Go to top of the page
4.4 Special warnings and precautions for use

In infants, high surface area in relation to mass raises the likelihood of uptake of excessive amounts of steroid from the cream, even without occlusion, thus adrenal suppression is more likely. In infants, long term continuous topical therapy should be avoided.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

There is no specific data available regarding the use in pregnant women and during lactation.

Pregnancy:

Evidence from animal studies suggests that prolonged intensive therapy with steroids during pregnancy should be avoided.

Lactation:

Given the slow uptake of hydrocortisone from the skin and the rapid destruction of hydrocortisone by the body, there would seem to be little risk of significant transfer at lactation.


Go to top of the page
4.7 Effects on ability to drive and use machines

None known.


Go to top of the page
4.8 Undesirable effects

If applied to open wounds or mucous membranes the hypertonic and acidic nature of the preparation may produce smarting. In such cases wash off with water. Where smarting is a barrier to therapy, dilute with an equal quantity of aqueous cream: after a week of treatment with this material, the normal strength should be tolerated.


Go to top of the page
4.9 Overdose

The barrier function in the skin to steroid uptake, the low toxicity of hydrocortisone and the nature mechanism for its rapid inactivation make overdose unlikely.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Corticosteroids, weak, other combinations

ATC code: D07XA

Urea at a concentration of 10% has keratolytic, anti microbial, anti pruritic and hydrating effects on the skin, properties also attributable to Lactic acid. Hydrocortisone 1% is the normal concentration of the drug used as a dermatological anti-inflammatory agent. In some patients with eczema, Calmurid HC cream may be as effective as fluorinated steroid creams.


Go to top of the page
5.2 Pharmacokinetic properties

Not applicable.


Go to top of the page
5.3 Preclinical safety data

Urea, lactic acid and hydrocortisone are long established materials, whose pre-clinical profile is known.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Glyceryl Monostearate

Betaine Monohydrate

Diethanolamine Cetylphosphate ("Amphisol")

Hard Fat

Cholesterol

Sodium Chloride

Purified Water


Go to top of the page
6.2 Incompatibilities

Do not mix with other preparations, as the effect on the stability of each is unknown. Do not pack in alloy containers as they may react with the lactic acid.


Go to top of the page
6.3 Shelf life

2 years


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C.


Go to top of the page
6.5 Nature and contents of container

Polypropylene tubes.

Package sizes: 15, 30, 50g 100 g.

Not all pack sizes may be marketed.


Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Galderma (UK) Limited,

Meridien House

69-71 Clarendon Road

Watford

Herts.

WD17 1DS

UK


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 10590/0010


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

23rd February 2006


Go to top of the page
10. DATE OF REVISION OF THE TEXT

September 2009



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/690/SPC/


Active Ingredients/Generics

 
   hydrocortisone
   urea
   lactic acid